Capital Rx stock
Private-market facts for current and former Capital Rx employees researching their stock.
Overview
Capital Rx is a health technology company that provides a cloud-based pharmacy benefits platform (JUDI) to employers, health plans, and PBMs, delivering transparent and lower-cost prescription drug management.
Selling Capital Rx shares
Why shareholders consider selling
Shareholders in Capital Rx may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Capital Rx does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Capital Rx stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Capital Rx shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Capital Rx shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Capital Rx shareholders
Exploring equity in Capital Rx often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Capital Rx most recently raised a Series C round . Total funding raised to date is approximately $378M.
Lead investors in this round include General Atlantic and Transformation Capital.
Founders & company background
Capital Rx was founded in 2017 by AJ Loiacono and is headquartered in New York, NY.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Capital Rx still a private company?
- Yes, Capital Rx is currently a private company.
- What is Capital Rx's latest funding round?
- Capital Rx's most recent known round is Series C.
- What is Capital Rx's valuation?
- Capital Rx's valuation has not been publicly disclosed.
- Who are the investors in Capital Rx?
- Notable investors include General Atlantic, Transformation Capital.
- Can I sell my Capital Rx stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Capital Rx stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Capital Rx data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.